Mode
Text Size
Log in / Sign up
N/A N=218 Randomized Single-blind Treatment

Clinical Comparison of the Airway Devices

Endotracheal Intubation · Supraglottic Airway

Enrolled (actual)
218
Serious AEs
0.0%
Results posted
Mar 2010
Primary outcome: Primary: Duration of Intubation — 30.9; 30.8; 30.17 seconds

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
LTS-D (Device); ProSeal Laryngeal Mask Airway (Device); Esophageal Tracheal Combitube (ETC) (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
The University of Texas Health Science Center, Houston
Primary completion
Apr 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Duration of Intubation
30.9; 30.8; 30.17
PRIMARY
Number of Participants With a Successful First Attempt Placement
65; 49; 52
PRIMARY
Number of Patients Who Required Multiple Attempts.
8; 24; 20 0.013 sig
PRIMARY
Leak Pressures
25.9; 23.5; 24.4 0.006 sig
PRIMARY
Post Operative Morbidity
10; 39; 5 0.003 sig
PRIMARY
Number of Failed Cases
4; 9; 5

Summary

The purpose of this study is to evaluate a new supra-glottic airway device, the "Disposable Laryngeal Tube Suction" (LTS-D; King Systems, Noblesville, IN). We propose to test its ease of insertion, position within the airway, patency of drain tube and anatomic sealing properties during spontaneous ventilation in anesthetized patients. The study device will be compared to the ProSeal Laryngeal Mask Airway (PLMA, LMA North America Inc.) and the Esophageal Tracheal Combitube (ETC; Tyco Healthcare/Mallinckrodt Nellcor, Pleasanton, Calif).

Eligibility Criteria

Inclusion Criteria

  • The subjects will be adult surgical candidates aged 18-80, ASA I-III, Mallampati I or II, presenting for elective surgery who require general anesthesia in whom tracheal intubation is not necessary.
  • Both male and female patients will be included.

Exclusion Criteria

  • Patients will be excluded from the study if they present as Mallampati III or IV, ASA IV-V or emergency status. Additionally, they will be excluded if they meet one of the contraindication criteria of the LMA ProSeal including:
  • Obesity
  • Pregnancy
  • History of gastric regurgitation, heart burn, ileus or "full stomach"
  • History of low pulmonary compliance or high pulmonary resistance
  • Known history of difficult endotracheal intubation or signs suggesting the possibility of difficult intubation
  • Pharyngeal pathology or
  • Upper airway obstruction due to laryngeal pathology.
  • Additionally, they will be excluded if they meet one of the contraindication criteria for the Combitube including:
  • Intact gag reflexes
  • Height <4 feet
  • Central airway obstruction
  • Recent ingestion of caustic substances
  • Known esophageal pathology, or
  • Known latex allergy.
  • They will also be excluded if any tracheal disease is present such as tracheal tumors, stenosis or previous tracheal surgery.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00581386). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search